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Background: Transcatheter aortic valve implantation (TAVI) has been designed to treat
elderly patients with severe aortic stenosis at high risk for surgery; however these patients
are also often affected by severe iliac-femoral arteriopathy, rendering the trans-femoral
approach unemployable.
Methods: All European centres with experience of Corevalve implantation through a
direct aortic approach were surveyed. All the 15 centers with 3 or more implants were
invited to contribute procedural data and outcomes onto a dedicated database.
Results: This multi-centre experience comprises 151 patients treated in the 15 centre in
9 countries in Europe and Israel. The mean age was 80.86.4 years, 46% of patients were
female. The mean logistic EuroScore was 26.616; 85% of patients were in NYHA
functional class  III. Echocardiographic max trans-valvular gradient was 80 mmHg and
left ventricle ejection fraction was 50%. Peripheral vascular disease was present in 86%
of cases and was the main reason for femoral TAVI exclusion. Fifty four % of patients had
coronary artery disease and 28% of the patients had undergone previous coronary artery
bypass surgery. The procedure was performed in 62% of cases via a mini-sternotomy and
in 58 patients through a right anterior mini-thoracotomy in the 2nd intercostal space. The
CoreValve 29 mm was implanted in 50% of the cases. In all patients after valve
deployment, the mean aortic gradient immediately dropped to  5 mmHg. Procedural
success was achieved in 97% of cases. There were no procedural deaths and 30 day
mortality was 8.6%. The incidence of stroke was 3.9% and 7/52 required a new permanent
pacemaker 20% of patients. Median post-operative hospitalization was 10 days.
Conclusions: Direct aortic access is a feasible approach for TAVI with the self-
expanding Corevalve prosthesis. These initial results with this technique are encouraging
given the high risk patient cohort (with a particularly high incidence of concomitant
vascular disease) and the fact that this series includes each unit’s initial experience and
early learning curve with this approach. In our opinion, the direct aortic approach should
be considered a viable alternative to the standard transapical technique.
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Background: Aortic regurgitation after transcatheter aortic valve replacement (TAVR)
occurs frequently and has been associated with increased mortality. An accurate prediction of
the in-vivo stent frame geometry based on pre-operative imaging may help to assess the risk
on regurgitation prior to the intervention and to choose optimal device size.
Methods: A patient-specific 3D model of the native aortic root was created from pre-TAVR
contrast multislice CT (MSCT) for ten patients who received a 26 or 29mm Medtronic
CoreValve system (MCS). An accurate finite element computer model was developed of the
26 and 29mm MCS frame based on a detailed evaluation of frame morphology (overall frame
dimensions, strut thickness) using micro-computed tomography and bench testing of the
physical frame characteristics (radial strength/stiffness). The MCS computer models were then
virtually implanted in these ten patients using finite element modelling to predict the final MCS
geometry. MSCT after TAVR was used to evaluate the MCS geometry obtained by the
computer simulations. For both the observed MCS (MSCT post) and the predicted MCS
(computer model), axial geometry of the frame was evaluated at 4 levels: 1) the ventricular end
2) nadir and 3) central coaptation of the MCS leaflets and 4) commissures. An area-based
diameter was derived at each level.
Results: The predicted MCS diameters correlate well with the MCS diameters derived
from post-operative MSCT (ventricular end: r 0.804, p 0.005; nadir: r 0.821, p
0.0036; central coaptation: r  0.681, p  0.0302; commissures: r  0.972, p  0.001),
with a slight underestimation of the frame diameters predicted by the computer model,
except at the level of central coaptation (ventricular end: 0.0051.531mm; nadir:
0.250.777mm; central coaptation: 0.0870.5mm; commissures:1.2491.133mm).
Conclusions: Based on native patient anatomy obtained from MSCT a computer
generated model accurately predicted the final geometry that the MCS frame achieved
after TAVR. These model predictions provide useful pre-operative insights and can help
to assess the risk on aortic regurgitation prior to the intervention.
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Background: Transcatheter Aortic Valve Replacement (TAVR) is now an established
treatment for patients with severe symptomatic aortic valve stenosis and prohibitive or
high surgical risk.There is limited data and experience with TAVR in the treatment of
patients with pure severe native valve aortic regurgitation.We aimed to evaluate the
off-label treatment of TAVR in pure native aortic valve regurgitation (NAR) for patients
with prohibitive surgical risk by examining the procedural and clinical results from a
worldwide registry of patients with severe NAR treated with TAVR.
Methods: Data on baseline patient characteristics, device and procedural parameters,
echocardiographic parameters and outcomes up to May 2012 were collected from 12
centres that have performed TAVR for NAR.
Results: A total of 31 patients underwent TAVR with the CoreValve prosthesis
(Medtronic, Minneapolis, MN) in 12 centres(mean age 74.8 9.5 years,58% female,Lo-
gistic EUROSCORE 28.118.6% STS score of 10.35.7%,25/31 transfemoral 3
subclavian approach,1 carotid and 1 transaortic approach).All patients had severe NAR
without aortic stenosis and 11/31(35.4%) of patients annular calcification documented on
CT, Echo or angiography.Implantation was successful in 96.7% of cases, but 19.4%(n6)
of patients required a second valve during the index procedure for residual AR.In all cases
where a second valve was needed annular calcification was absent(6/31 patients,RR 7.42,
95% CI 0.45-120.6,p0.16).Grade I or less aortic regurgitation was present post
procedurally in 77.4% of patients(n24grade I,n5 grade II,n2 grade 3).The all
cause 30-day mortality was 6.4%(n2)one of which was a cardiovascular mortality.The
30-day major stroke rate was 6.4%(n2)and there were no myocardial infarctions
according to the Valve Academic Research Consortium(VARC) definitions.At 12 months
the all cause mortality was 12.5%(n3/24),2 of which were cardiovascular mortality.
Conclusions: This represents the first registry analysis of patients being treated with
TAVR for the indication of severe NAR.This study shows that TAVR for pure severe
native valve aortic regurgitation is feasible and can be an effective treatment for patients
with prohibitive surgical risk.
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Background: Percutaneous coronary intervention (PCI) is less commonly performed in
women, and studies of elective PCI have demonstrated higher early mortality among
women than among men. Transcatheter aortic valve implantation (TAVI) is increasingly
used for high-risk patients with severe aortic stenosis, but the impact of gender on baseline
characteristics and outcome of TAVI patients is unclear.
Methods: 222 patients underwent TAVI at a single institution and were prospectively
included in a dedicated database. The proportion of women (56.8%) was higher than that
of men. Both Medtronic CoreValve (83.3%) and Edwards Sapien XT valve were used;
both were implanted almost exclusively through the transfemoral approach (98%).
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